🟢 Icecure Medical is trading 8.6% up in pre-market after first patients enrolled in U.S. ChoICE study

Icecure Medical is trading at $1.14, up 8.57% in pre-market after its announcement of enrollment in the ChoICE study.

• On October 20, the company said the first two patients enrolled at U.S. sites in its FDA-approved ChoICE study of ProSense breast cancer cryoablation.
• The announcement preceded the regular session; reporting noted no clear late-breaking catalyst for the later after-hours rise.
• Nasdaq futures were up 0.71%; no pre-market volume figures were provided.